Kinney A Y, Sahin A, Vernon S W, Frankowski R F, Annegers J F, Hortobagyi G N, Buzdar A U, Frye D K, Dhingra K
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Cancer. 1997 Dec 15;80(12):2240-9. doi: 10.1002/(sici)1097-0142(19971215)80:12<2240::aid-cncr4>3.0.co;2-y.
Sialyl-Tn (STn) represents an aberrantly glycosylated mucin epitope that is expressed in breast carcinoma and other adenocarcinomas and is an important factor in the development of novel immunotherapeutic approaches. The primary aim of the current study was to investigate the influence of STn expression on the prognoses of patients with breast carcinoma.
A cohort of 207 women diagnosed with invasive breast carcinoma who were treated with anthracycline-containing adjuvant chemotherapy and were enrolled in a randomized clinical trial were studied. Expression of STn was determined by an immunohistochemical procedure in which the B72.3 monoclonal antibody was used. Kaplan-Meier and Cox proportional regression survival analyses were used to compare low STn and high STn patients.
Forty-eight (23%) of the 207 specimens demonstrated high STn staining (>25% cells were immunoreactive). During a median follow-up of 5 years, high STn patients had worse disease free survival than low STn patients (55% vs. 74%, respectively; P = 0.03). High STn expression was significantly associated with age (P = 0.04) but not with other conventional prognostic markers. In multivariate analysis using the Cox regression model, high STn emerged as an independent prognostic indicator for disease free survival (hazard ratio [HR], 2.02; 95% confidence interval [CI], 1.09-3.73) and for overall survival (HR, 2.16; 95% CI, 0.95-4.92).
The results of this study suggest that STn may be a valuable marker for identifying women at high risk of developing recurrent breast carcinoma who may be candidates for trials investigating new therapies in combination with standard adjuvant therapy.
唾液酸化-Tn（STn）是一种异常糖基化的黏蛋白表位，在乳腺癌和其他腺癌中表达，是新型免疫治疗方法开发中的一个重要因素。本研究的主要目的是探讨STn表达对乳腺癌患者预后的影响。
对207名诊断为浸润性乳腺癌且接受含蒽环类辅助化疗并参加随机临床试验的女性进行队列研究。采用免疫组化方法，使用B72.3单克隆抗体测定STn的表达。采用Kaplan-Meier法和Cox比例回归生存分析比较低STn和高STn患者。
207份标本中有48份（23%）显示高STn染色（>25%的细胞呈免疫反应性）。在中位随访5年期间，高STn患者的无病生存率低于低STn患者（分别为55%和74%；P = 0.03）。高STn表达与年龄显著相关（P = 0.04），但与其他传统预后标志物无关。在使用Cox回归模型的多变量分析中，高STn成为无病生存（风险比[HR]，2.02；95%置信区间[CI]，1.09 - 3.73）和总生存（HR，2.16；95% CI，0.95 - 4.92）的独立预后指标。
本研究结果表明，STn可能是一种有价值的标志物，用于识别有复发性乳腺癌高风险的女性，这些女性可能是结合标准辅助治疗研究新疗法试验的候选者。
